Close menu




Biotechnology

Photo credits: pixabay.com

Commented by Fabian Lorenz on October 11th, 2023 | 08:10 CEST

Attention Price Jump! Tui, Plug Power and Defence Therapeutics with News

  • Biotechnology
  • Innovations
  • Technology
  • Travel

Alarm at Tui and Deutsche Lufthansa. Both stocks are influenced by the terrorist attack in Israel this week. While the oil price is surging, aviation and tourism stocks are declining. The Tui share had already been trending weakly before. Even the leap into the profit zone could not change this. And what do analysts say? Meanwhile, Defence Therapeutics shone with positive news on a cancer therapy. As a result, the biotech share gained yesterday, offering further potential for price increases. Plug Power's share price rose by a good 7% yesterday. What is behind this?

Read

Commented by Fabian Lorenz on October 5th, 2023 | 07:10 CEST

Buy biotech stocks now? BioNTech, Morphosys and Cardiol Therapeutics in check

  • Biotechnology
  • Pharma

In times of high interest rates, the wheat is separated from the chaff, even in the biotech sector. After all, young research-based companies, in particular, have a high demand for capital. But at the moment, all companies are being lumped together. This opens up clear buying opportunities because some have full coffers. BioNTech belongs to this group. Thanks to the COVID-19 vaccine, research is fully financed. The same goes for Cardiol Therapeutics. The share of the Canadians is one of the summer's high flyers, and the recent price setback offers an entry opportunity. The analysts' price target is over 300% above the current level. And what do analysts say about the German biotech veteran Morphosys? Goldman Sachs has tripled its price target.

Read

Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

  • Biotechnology
  • Pharma
  • Investments

According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

Read

Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

  • Biotechnology
  • Pharma

High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!

Read

Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

  • Biotechnology
  • Pharma
  • Electromobility

Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.

Read

Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

  • AI
  • Biotechnology
  • Investments

The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and C3.ai. However, the biotech sector has recently started to climb again. Where are the opportunities for investors?

Read

Commented by Nico Popp on September 13th, 2023 | 08:30 CEST

Biotech: Poison cocktail or miracle cure? Defence Therapeutics, MorphoSys, Pfizer

  • Biotechnology
  • Pharma

Biotech stocks represent both light and dark. At the end of 2020, BioNtech turned the tide of the pandemic with its Comirnaty vaccine. But many shareholders have also had to endure losses. An example of a loss-maker is the share of the SDAX stock MorphoSys. Between 2020 and 2022, the share lost more than 80%. But what were the reasons for the decline? Are there biotech companies that offer better prospects? We shed light on three stocks from the biotech and healthcare sectors.

Read

Commented by Stefan Feulner on September 12th, 2023 | 07:10 CEST

Trend-setting developments at Covestro, Cardiol Therapeutics and 2G Energy AG

  • Biotechnology
  • Energy
  • Innovations

The holiday season is drawing to a close. By Tuesday at the latest, when the last German state concludes its school holidays, every investment banker will be back at their screens, closely monitoring the most exciting events on the markets. Despite the summer lull, there have been many impactful events, especially in second-tier companies, which could significantly impact share prices in the near future.

Read

Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST

The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth

  • Cannabis
  • Biotechnology

Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?

Read

Commented by Stefan Feulner on September 7th, 2023 | 08:00 CEST

Biotech with tailwind - Newron Pharmaceuticals, Defence Therapeutics, BioNTech

  • Biotechnology
  • Pharma

There is a lot of activity in the biotechnology sector, even though the broadly diversified Nasdaq Biotech Index reflects this with a performance of only 1% since the beginning of the year. In addition to the increasing number of acquisitions by Big Pharma, promising technologies from second-tier companies are performing extremely well. Furthermore, the surging COVID-19 statistics are instilling hope in vaccine producers as they aim to revive their slumping sales.

Read